Biotech company Admedus has initiated a capital raising comprising a placement and rights issue, with the hope of generating up to $28 million to fund ongoing development of various health care programs.
Biotech company Admedus has completed an oversubscribed $8 million share placement as it looks to push marketing for its CardioCel regenerative tissue product in Europe and the US.
